MDR-TB patients in KwaZulu-Natal, South Africa: Cost-effectiveness of 5 models of care
Open Access
- 18 April 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (4) , e0196003
Abstract
South Africa has a high burden of MDR-TB, and to provide accessible treatment the government has introduced different models of care. We report the most cost-effective model after comparing cost per patient successfully treated across 5 models of care: centralized hospital, district hospitals (2), and community-based care through clinics or mobile injection teams. In an observational study five cohorts were followed prospectively. The cost analysis adopted a provider perspective and economic cost per patient successfully treated was calculated based on country protocols and length of treatment per patient per model of care. Logistic regression was used to calculate propensity score weights, to compare pairs of treatment groups, whilst adjusting for baseline imbalances between groups. Propensity score weighted costs and treatment success rates were used in the ICER analysis. Sensitivity analysis focused on varying treatment success and length of hospitalization within each model. In 1,038 MDR-TB patients 75% were HIV-infected and 56% were successfully treated. The cost per successfully treated patient was 3 to 4.5 times lower in the community-based models with no hospitalization. Overall, the Mobile model was the most cost-effective. Reducing the length of hospitalization and following community-based models of care improves the affordability of MDR-TB treatment without compromising its effectiveness.Keywords
Funding Information
- United Way Worldwide grant (17245)
- Izumi Foundation
- National Institute of Allergy and Infectious Diseases (K23AI083088, P30AI051519)
- University Research Corporation (URC) South Africa
This publication has 24 references indexed in Scilit:
- Association between Health Systems Performance and Treatment Outcomes in Patients Co-Infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: Implications for TB ProgrammesPLOS ONE, 2014
- A Systematic Review of the Effectiveness of Hospital- and Ambulatory-Based Management of Multidrug-Resistant TuberculosisThe American Journal of Tropical Medicine and Hygiene, 2013
- What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?PLOS ONE, 2013
- Costs of inpatient treatment for multi‐drug‐resistant tuberculosis in South AfricaTropical Medicine & International Health, 2012
- Median-Based Incremental Cost-Effectiveness Ratio (ICER)Journal of Statistical Theory and Practice, 2012
- Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and RussiaEuropean Respiratory Journal, 2012
- A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant TuberculosisPharmacoEconomics, 2012
- Drug-Resistant Tuberculosis, KwaZulu-Natal, South Africa, 2001–2007Emerging Infectious Diseases, 2011
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South AfricaAIDS, 2009